TGA / PMDA / NMPA · Asia-Pacific
risankizumab — TGA / PMDA / NMPA regulatory status
risankizumab (SKYRIZI) regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: TGA approved · PMDA approved.
Status snapshot
- Status
- TGA approved · PMDA approved
- Brand
- SKYRIZI
- Originator
- AbbVie
- Mechanism
- Interleukin-23 inhibitor
- Target
- Interleukin-23
- Structured fields
- 9
Sponsor / originator context: AbbVie. Pipeline programs and exclusivity signals below are joined from ClinicalTrials.gov-linked projects and USPTO/EPO patent rows associated with this INN.
Pharmacology context used for competitive intelligence: Interleukin-23 inhibitor. Target: Interleukin-23. This page is a status aggregation for professional reference — not prescribing advice.
Regional decision snapshot — TGA: approved; PMDA: approved.
Linked evidence on this spoke: 0 published clinical programs and 1 related patent record. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 2025137347 | FORMULATIONS DE RISANKIZUMAB À HAUTE CONCENTRATION | WO |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of risankizumab?
risankizumab currently shows TGA approved · PMDA approved in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get risankizumab regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.